The Costs of Non-Muscle Invasive Bladder Cancer

Urologic Clinics of North America

Volumn 40, Issue 2, 2013, Pages 261-269

  James, Andrew C ^a   Gore, John L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Cost effectiveness; Quality of care

Indexed keywords

BCG VACCINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOMYCIN; TUMOR ANTIGEN;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYSTECTOMY; CYSTOSCOPY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG COST; EVIDENCE BASED MEDICINE; FGFR3 GENE; FUNCTIONAL STATUS; GENE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERMETHOD COMPARISON; NARROW BAND IMAGING; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RECURRENCE RISK; REIMBURSEMENT; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SOCIAL INTERACTION; SOCIAL STATUS; URINE CYTOLOGY;

COST OF ILLNESS; HUMANS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84876705853     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.01.004     Document Type: Review

References (64)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
2. Jones J.S., Larchian W.A. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh urology 2012, 2335-2354. Saunders, Philadelphia. 10 edition. A.J. Wein, L.R. Kavoussi, A.C. Novick (Eds.).
3. Mariotto A.B., Yabroff K.R., Shao Y., et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103(2):117-128.
4. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21(18):1315-1330.
5. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33(8):828-841.
6. Edge S.B., American Joint Committee on Cancer, American Cancer Society AJCC cancer staging handbook: from the AJCC cancer staging manual 2010, Springer, New York. 7th edition.
7. Eble J.N., Sauter G., Epstein J.I., et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC Press, Lyon.
8. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22(12):1435-1448.
9. Donat S.M. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003, 30(4):765-776.
10. Gandini S., Botteri E., Iodice S., et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008, 122(1):155-164.
11. Wood D.P. Urothelial tumors of the bladder. Campbell-Walsh urology 2012, 2309-2334. Saunders, Philadelphia. 10 edition. A.J. Wein, L.R. Kavoussi, A.C. Novick (Eds.).
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
13. Hayat M.J., Howlader N., Reichman M.E., et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12(1):20-37.
14. Avritscher E.B., Cooksley C.D., Grossman H.B., et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006, 68(3):549-553.
15. Han M., Schoenberg M.P. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000, 5(3):87-92.
16. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999, 162(1):74-76.
17. Dutta S.C., Smith J.A., Shappell S.B., et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001, 166(2):490-493.
18. Montie J.E., Clark P.E., Eisenberger M.A., et al. Bladder cancer. J Natl Compr Canc Netw 2009, 7(1):8-39.
19. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163(4):1124-1129.
20. Kilbridge K.L., Kantoff P. Intravesical therapy for superficial bladder cancer: is it a wash?. J Clin Oncol 1994, 12(1):1-4.
21. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996, 155(4):1233-1238.
22. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004, 171(6 Pt 1):2186-2190. [quiz: 2435].
23. Marchetti A., Wang L., Magar R., et al. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000, 22(4):422-438.
24. Smith JA, Labasky RF, Montie JE, et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 Update. 2007. Available at: Accessed December 3, 2012. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bladcan07/chapter1.pdf.
25. Brausi M., Witjes J.A., Lamm D., et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186(6):2158-2167.
26. Holmang S., Johansson S.L. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002, 167(4):1634-1637.
27. Mariappan P., Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005, 173(4):1108-1111.
28. Hemani M.L., Makarov D.V., Huang W.C., et al. The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer. Cancer 2010, 116(5):1264-1271.
29. Mowatt G., Zhu S., Kilonzo M., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14(4):1-331. iii-iv.
30. Raitanen M.P. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008, 26(1):45-50.
31. Mian C., Pycha A., Wiener H., et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999, 161(5):1486-1489.
32. Olsson H., Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001, 35(4):280-282.
33. Nguyen C.T., Jones J.S. Defining the role of NMP22 in bladder cancer surveillance. World J Urol 2008, 26(1):51-58.
34. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003, 61(1):109-118. [discussion: 118].
35. Halling K.C., Kipp B.R. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 2008, 15(5):279-286.
36. Moonen P.M., Merkx G.F., Peelen P., et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007, 51(5):1275-1280. [discussion: 1280].
37. Savic S., Zlobec I., Thalmann G.N., et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical bacillus Calmette-Guerin therapy. Int J Cancer 2009, 124(12):2899-2904.
38. Kamat A.M., Karam J.A., Grossman H.B., et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011, 108(7):1119-1123.
39. Cauberg E.C., Mamoulakis C., de la Rosette J.J., et al. Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol 2011, 29(4):503-509.
40. Stenzl A., Burger M., Fradet Y., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010, 184(5):1907-1913.
41. Gilbert S.M., Dunn R.L., Hollenbeck B.K., et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol 2010, 183(5):1764-1769.
42. Gilbert S.M., Wood D.P., Dunn R.L., et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007, 109(9):1756-1762.
43. Cella D.F. FACIT manual. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) scales version 4 1997, Evanston Northwestern Healthcare and Northwestern University, Evanston (IL).
44. Sprangers M.A., Cull A., Groenvold M., et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998, 7(4):291-300.
45. Yoshimura K., Utsunomiya N., Ichioka K., et al. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology 2005, 65(2):290-294.
46. Mack D., Frick J. Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. Br J Urol 1996, 78(3):369-371.
47. Allareddy V., Kennedy J., West M.M., et al. Quality of life in long-term survivors of bladder cancer. Cancer 2006, 106(11):2355-2362.
48. Hemani M.L., Bennett C.L. The excessive cost of early stage bladder cancer care: are providers really to blame?. Cancer 2010, 116(15):3530-3532.
49. Madeb R., Golijanin D., Noyes K., et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009, 115(12):2660-2670.
50. Chamie K., Saigal C.S., Lai J., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011, 117(23):5392-5401.
51. Lee C.T., Barocas D., Globe D.R., et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol 2012, 188(6):2114-2119.
52. Schrag D., Hsieh L.J., Rabbani F., et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003, 95(8):588-597.
53. Hollenbeck B.K., Ye Z., Dunn R.L., et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009, 101(8):571-580.
54. Hollingsworth J.M., Zhang Y.S., Miller D.C., et al. Identifying better practices for early-stage bladder cancer. Med Care 2011, 49(12):1112-1117.
55. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24(22):3664-3671.
56. van Oers J.M., Zwarthoff E.C., Rehman I., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009, 55(3):650-657.
57. van Kessel K.E., Kompier L.C., de Bekker-Grob E.W., et al. FGFR3 mutation analysis on voided urine samples to reduce cystoscopies and cost in non-muscle invasive bladder cancer surveillance: a comparison of three different strategies. J Urol 2012, [Epub ahead of print].
58. Pruthi R.S., Baldwin N., Bhalani V., et al. Conservative management of low risk superficial bladder tumors. J Urol 2008, 179(1):87-90. [discussion: 90].
59. Birkmeyer N.J., Share D., Campbell D.A., et al. Partnering with payers to improve surgical quality: the Michigan plan. Surgery 2005, 138(5):815-820.
60. Flum D.R., Fisher N., Thompson J., et al. Washington State's approach to variability in surgical processes/outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP). Surgery 2005, 138(5):821-828.
61. Share D.A., Campbell D.A., Birkmeyer N., et al. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff (Millwood) 2011, 30(4):636-645.
62. Kwon S., Florence M., Grigas P., et al. Creating a learning healthcare system in surgery: Washington State's Surgical Care and Outcomes Assessment Program (SCOAP) at 5 years. Surgery 2012, 151(2):146-152.
63. Miller D.C., Murtagh D.S., Suh R.S., et al. Establishment of a urological surgery quality collaborative. J Urol 2010, 184(6):2485-2490.
64. Miller D.C., Murtagh D.S., Suh R.S., et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol 2011, 186(3):844-849.